Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the standard of care for patients with autoimmune and inflammatory diseases. The company utilizes its expertise in immunobiology and drug discovery to develop innovative therapies targeting key signaling nodes in disease pathways. Their lead programs include OD-001 and OD-002, which aim to address significant unmet medical needs in conditions like ulcerative colitis and systemic lupus erythematosus.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $3.0M | $4.5M | Not provided |
| YoY Growth | -33.3% | - | - |
| Adjusted Net Loss | -$148.6M | -$129.3M | Not provided |
| Margin % | -4953.3% | -2873.3% | - |
Based on price range midpoint and most recent fiscal year data.
The company operates in the biopharmaceutical industry, specifically targeting autoimmune and inflammatory diseases. The company competes with established players in the field, although specific competitor names are not mentioned in the filing.
Proceeds from the IPO are expected to be used for advancing their clinical programs and supporting ongoing research and development efforts.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.